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Purpose: Congestive heart failure is characterized by an adverse structural remodeling of the myocardium. Osteopontin is a glycoprotein being 
expressed in cardiomyocytes and fibroblasts. Osteopontin is involved in extracellular matrix formation and acts as a mediator of myocardial 
remodeling and fibrosis. This study evaluates serum levels of ostepontin in patients suffering from acute congestive heart failure (aCHF).
Patients and Methods: 80 patients presenting with symptoms of acute dyspnea and/or peripheral edema in the emergency department were 
evaluated. Patients with a prior history of fibrotic diseases other than aCHF accounting for dyspnea or edema, such as a history of neoplastic, 
hepatic, infectious and collagen disease were excluded. Blood samples for measurement of osteopontin (Quantikine®, R&D Systems, Inc) were 
collected immediately after the initial clinical presentation.
Results: Mean osteopontin levels were significantly higher in patients with aCHF (184.5 ng/ml, n=40) compared to patients without (140.5 ng/
ml, n=40) (P=0.03). Osteopontin levels were significantly higher in patients of NYHA class III/IV (207.7 ng/ml, n=33) compared to those of NYHA 
class I/II (128.8 pg/ml, n=17) (P=0.002). Accordingly, osteopontin levels were significantly higher in patients of ACC/AHA class C/D (178.9 ng/ml, 
n=54) compared to those of class A/B (119.7 ng/ml, n=21) (P=0.008). Patients with a left ventricular dysfunction had significantly higher levels of 
Osteopontin (199.0 ng/ml, n=25) than those without (146.0 ng/ml, n=54) (P=0.006). Mortality rates were 13% (10/80) at 1 year and 29% (23/80) 
at 5 years. Osteopontin levels were significantly higher in patients who died during clinical follow-up (1 year: 250.3 ng/ml vs. 149.5 ng/ml, P=0.006; 
5 years: 201.6 vs. 147.0 ng/ml; P=0.009).
Conclusions: Osteopontin plasma levels were increased in patients suffering from aCHF. Osteopontin was associated with functional NYHA, 
structural AHA/ACC classification and left ventricular dysfunction. Increased levels of osteopontin might indicate patients with aCHF at higher 
functional or structural disease stages and might predict 1- and 5-year mortality in high risk aCHF patients.
